Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVD-133214 and Pembrolizumab in Advanced Colorectal Cancer
NCT07811193Phase 2Recruiting
- Sponsor
- Vividion Therapeutics
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 22
01
Overview
Phase 2, randomised, open-label trial of VVD-133214 in colorectal adenocarcinoma (3 arms), sponsored by Vividion Therapeutics. Primary endpoint: Landmark Progression-Free Survival Rate at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
VVD-133214
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07811193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811193.